TVTX
Travere Therapeutics Inc
NASDAQ: TVTX · HEALTHCARE · BIOTECHNOLOGY
$55.15
+1.87% today
Updated 2026-06-18
Market cap
$4.84B
P/E ratio
—
P/S ratio
9.03x
EPS (TTM)
$-0.50
Dividend yield
—
52W range
$14 – $53
Volume
2.4M
Travere Therapeutics Inc (TVTX) Financial Forecast & Price Target 2030
Research-backed projections from analyst consensus, management guidance, and sector analysis.
Research-backed TVTX price target 2030 projection accounting for share dilution, balance sheet debt, and time value of money.
Current price
$55.15
Today
Analyst consensus
$47.83
-13.27% · 12M
2030 Base
$47.27
-14.29% future
NPV today
$29.58
@ 11% WACC
13 analysts:
10 Buy2 Hold1 Sell
Management guidance
CEO Eric Dube has not publicly disclosed a specific 2030 revenue target. However, management's 2026 outlook implies $714M revenue (45.5% growth from $490.7M in 2025), and Q1 2026 results showed 55.6% YoY growth ($127.2M quarterly), positioning the company for strong 2026 execution. No specific CAGR guidance through 2030 has been disclosed.
Sources: Management guidance, analyst consensus, sector analysishigh confidence
TVTX · Travere Therapeutics Inc · Revenue & price projection · 2023–2030E
Actual / 2030 target Projected revenue Base case price Bull to bear range
Bear case (2030)
$6.52
NPV today: $4.08
Base case (2030)
$47.27
NPV today: $29.58
Bull case (2030)
$108.41
NPV today: $67.85
WallStSmart.com
TVTX financial forecast · Research-backed projections
| Metric | 2025 | 2026 (E) | 2027 (E) | 2028 (E) | 2029 (E) | 2030 (E) ★ |
|---|---|---|---|---|---|---|
| Revenue | $0.5B | $0.7B | $1.0B | $1.3B | $1.6B | $2.0B |
| Revenue growth | 110.5% | 45.5% | 38.7% | 33.3% | 25.0% | 20.0% |
| Net margin | — | 2.9% | 16.7% | 20.7% | 23.1% | 23.3% |
| EPS | $0.90 | $0.22 | $1.74 | $2.85 | $3.95 | $4.75 |
| Diluted shares | — | 94M | 95M | 96M | 96M | 97M |
| Net debt | — | $357.00M | $852.00M | $1.51B | $2.34B | $3.33B |
| P/S multiple | — | 4.0x | 4.0x | 4.0x | 4.0x | 4.0x |
| Implied price (base) | — | $26.61 | $32.76 | $39.37 | $44.18 | $47.27 |
★ 2030E is the model's terminal target year. Implied price = (Revenue × P/S − Net debt) ÷ Diluted shares.
Scenario detail · Three drivers, three outcomes
| 2030E driver | Bear | Base | Bull |
|---|---|---|---|
| Revenue | $2.0B | $2.0B | $2.0B |
| P/S multiple | 2.0x | 4.0x | 7.0x |
| Diluted shares | 97M | 97M | 97M |
| Net debt | $3.33B | $3.33B | $3.33B |
| Implied P/E † | 1x | 10x | 23x |
| 2030 Price | $6.52 | $47.27 | $108.41 |
| NPV @ 11% | $4.08 | $29.58 | $67.85 |
† Implied P/E: Multiples remain elevated across all three scenarios because TVTX is valued primarily on revenue scale during its growth phase, not near-term earnings power. Lower P/E in the bear case reflects multiple compression, but the absolute level stays high since 2030E still represents a hypergrowth-to-mature transition year.
EV to per-share bridge · How we get to $47.27 base case
TVTX catalysts and risks
Growth catalysts
+ FILSPARI FDA approval for FSGS (approved April 2026) — driving revenue acceleration in rare kidney disease market
+ FILSPARI label expansion for IgAN (additional indication under development) — expansion of TAM and addressable patient population
+ HCU (homocystinuria) trial restart and ongoing pipeline development — multiple revenue streams by 2028-2030
Key risks
- FILSPARI uptake slower than market expectations — kidney disease patient base is small (~20K-30K FSGS/IgAN combined in US); adoption depends on physician awareness and payer coverage
- Competition from Novartis FIDELIO-B (approved SGLT2i for FSGS) and other rare kidney therapies — market share compression if competitors gain traction
- High debt burden ($327.7M) with convertible notes refinancing — recent $525M convertible offering increases dilution risk if stock-based conversion occurs
Methodology · Travere Therapeutics Inc 2030 stock forecast model
Travere Therapeutics Inc 2030 price target is calculated using WallStSmart's research model. Revenue projections are derived from analyst consensus across 13 Wall Street analysts, management guidance from the latest earnings call, and sector growth forecasts. The model is built on five core components:
| 1. Share dilution | Projected from per-ticker schedule of SBC + equity raise activity, compounding year by year (4% cumulative for TVTX by 2030) |
| 2. Net debt | EV minus net debt yields equity value; debt projected from capex cycle trajectory ($3.33B by 2030) |
| 3. Time value | NPV calculated using 11% WACC (CAPM: beta 1.136) |
| 4. Multiple framework | P/S compresses with scale: bear 2.0x / base 4.0x / bull 7.0x |
| 5. Scenario design | Bull/Base/Bear vary revenue, margin, shares, debt, and multiple independently |
WallStSmart research model · Not financial advice · Past performance is not indicative of future results · Last researched: May 20, 2026.
TVTX price target FAQ
What is the TVTX price target for 2030?
WallStSmart's Travere Therapeutics Inc 2030 base case is $47.27 per share, with a bull case of $108.41 and bear case of $6.52. The NPV of the base case discounted to today at 11% WACC is $29.58.
How is the Travere Therapeutics Inc 2030 stock forecast calculated?
The TVTX 2030 projection multiplies projected revenue by a growth-adjusted P/S multiple to derive enterprise value, subtracts projected net debt to get equity value, then divides by diluted shares outstanding accounting for dilution from stock-based compensation and equity raises.
Why does the TVTX price target account for dilution?
Travere Therapeutics Inc is projected to grow diluted share count from 93M to 97M by 2030 (a 4% increase) through stock-based compensation and capital raises. Ignoring this would inflate the price target by approximately 4%.
What is the analyst consensus on TVTX stock?
13 analysts cover TVTX with an average 12-month price target of $47.83. The 2030 projection extends this framework with longer-horizon assumptions including dilution and time value of money.